» Articles » PMID: 19579009

Enhancing Immune Responses Against SARS-CoV Nucleocapsid DNA Vaccine by Co-inoculating Interleukin-2 Expressing Vector in Mice

Overview
Journal Biotechnol Lett
Date 2009 Jul 7
PMID 19579009
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The immunogenicity of SARS-CoV nucleocapsid DNA vaccine and the immunoregulatory activity of interleukin-2 (IL-2) were investigated. DNA vaccine plasmids, pcDNA-N and pcDNA-IL2, were constructed and inoculated into BALB/c mice with or without pcDNA-IL2 by intramuscular injection. Cellular and humoral immune responses were assessed by indirect ELISA, lymphocyte proliferation assays, ELISPOT and FACS. The nucleocapsid DNA vaccine had good immunogenicity and can induce specific humoral and cellular immunity in BALB/c mice, while IL-2 plays an immunoadjuvant role and enhances specific immune responses. This study provides a frame of reference for the design of DNA vaccines against SARS-CoV.

Citing Articles

Vaccination with outer membrane vesicles from Neisseria Meningitidis and SBa15, SBa16 mesoporous silica associated with SARS-CoV-2 induces protective humoral and cellular response against COVID-19 in mice.

Bernardes B, Moura A, Guarnieri J, Silva C, Costa H, Martins da Silva I Braz J Infect Dis. 2024; 28(6):104479.

PMID: 39547005 PMC: 11609543. DOI: 10.1016/j.bjid.2024.104479.


Advances in Infectious Disease Vaccine Adjuvants.

Fan J, Jin S, Gilmartin L, Toth I, Hussein W, Stephenson R Vaccines (Basel). 2022; 10(7).

PMID: 35891284 PMC: 9316175. DOI: 10.3390/vaccines10071120.


Development of synthetic antigen vaccines for COVID-19.

Invencao M, Melo A, Macedo L, da Costa Neves T, de Melo C, Cordeiro M Hum Vaccin Immunother. 2021; 17(11):3855-3870.

PMID: 34613880 PMC: 8506811. DOI: 10.1080/21645515.2021.1974288.


Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines.

Aida V, Pliasas V, Neasham P, North J, McWhorter K, Glover S Front Vet Sci. 2021; 8:654289.

PMID: 33937377 PMC: 8083957. DOI: 10.3389/fvets.2021.654289.


Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19.

Lee P, Kim D Immune Netw. 2020; 20(4):e28.

PMID: 32895615 PMC: 7458800. DOI: 10.4110/in.2020.20.e28.


References
1.
Stadler K, Masignani V, Eickmann M, Becker S, Abrignani S, Klenk H . SARS--beginning to understand a new virus. Nat Rev Microbiol. 2004; 1(3):209-18. PMC: 7097337. DOI: 10.1038/nrmicro775. View

2.
Hu H, Huang X, Tao L, Huang Y, Cui B, Wang H . Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model. Vaccine. 2009; 27(11):1758-63. PMC: 7115532. DOI: 10.1016/j.vaccine.2009.01.021. View

3.
Hu H, Lu X, Tao L, Bai B, Zhang Z, Chen Y . Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice. Clin Vaccine Immunol. 2007; 14(7):894-901. PMC: 1951058. DOI: 10.1128/CVI.00019-07. View

4.
Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt G . A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003; 348(20):1986-94. DOI: 10.1056/NEJMoa030685. View

5.
Geissler M, Gesien A, Tokushige K, Wands J . Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol. 1997; 158(3):1231-7. View